Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study.

[1]  E. D’Amico,et al.  Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study , 2021, Therapeutic advances in chronic disease.

[2]  J. Lechner-Scott,et al.  Risk of secondary progressive multiple sclerosis: A longitudinal study , 2019, Multiple sclerosis.

[3]  M. Ramanathan,et al.  Epidemiology and treatment of multiple sclerosis in elderly populations , 2019, Nature Reviews Neurology.

[4]  Devon S. Conway,et al.  Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60 , 2019, Multiple sclerosis.

[5]  J. Lechner-Scott,et al.  Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis , 2019, JAMA.

[6]  L. Thygesen,et al.  Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women , 2018, Neurology.

[7]  M. Sormani,et al.  Assessing association of comorbidities with treatment choice and persistence in MS , 2017, Neurology.

[8]  B. Laursen,et al.  Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  M. Ramanathan,et al.  Aging and multiple sclerosis , 2016, Multiple sclerosis.

[10]  A. Carpenter,et al.  Late onset multiple sclerosis: Is it really late onset? , 2014, Multiple sclerosis and related disorders.

[11]  Lynda Hillman.  Caregiving in multiple sclerosis. , 2013, Physical medicine and rehabilitation clinics of North America.

[12]  R. Fox,et al.  Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy , 2010, Multiple sclerosis.

[13]  V. Martinelli,et al.  Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis , 2004, Neurological Sciences.

[14]  Christian Confavreux,et al.  Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis , 2003, Journal of the Neurological Sciences.

[15]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[16]  Jared M. Bruce,et al.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions. , 2021, Missouri medicine.